Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is being developed as a treatment for moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, which is being developed as a treatment for psoriasis and/or inflammatory bowel disease. It also provides contract research services. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
IPO Year: 2015
Exchange: NASDAQ
Website: aclaristx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/28/2025 | $8.00 | Outperform | Wedbush |
| 3/18/2025 | Overweight | Cantor Fitzgerald | |
| 12/23/2024 | $20.00 | Neutral → Buy | H.C. Wainwright |
| 11/20/2024 | Neutral → Overweight | Cantor Fitzgerald | |
| 11/19/2024 | $2.00 → $7.00 | Market Perform → Outperform | Leerink Partners |
| 11/19/2024 | $8.00 | Neutral → Buy | BTIG Research |
| 11/19/2024 | $2.00 → $7.00 | Hold → Buy | Jefferies |
| 11/18/2024 | $3.00 → $13.00 | Neutral → Overweight | Piper Sandler |
| 1/22/2024 | Buy → Neutral | H.C. Wainwright | |
| 11/13/2023 | Outperform → Mkt Perform | William Blair |